Home › Products › Infectious Disease › Taficita Tablet
Taficita Tablet
Salt Composition: EMTRICITABINE,TENOFOVIR ALAFENAMIDE
- Manufacturer: MYLAN PHARMACEUTICALS PVT LTD
- Pack Size: 30 TABLET(s) IN A BOTTLE
- Dosage Form: TABLET
- Strength: 200MG+25MG
- Prescription Required
- Storage: Store Taficita tablet below 30°C Protect the medicine from light and excessive moisture. Keep the medicine out of reach of children and pets If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
₹1100.00₹1996.88
Inclusive of all taxes
Product Introduction
Taficita tablet contains the active ingredients Emtricitabine and tenofovir alafenamide. It is a combination antiretroviral medication. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). It is indicated in combination with other medicines for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents aged 12 years and above who weigh at least 35 kg. Both components work by slowing HIV replication in the body.
Do not take Taficita tablet if you are allergic to Emtricitabine, tenofovir alafenamide, or any other ingredient in the formulation. Patients using this medicine should undergo regular HIV infection testing. Do not omit any doses or discontinue this medicine without medical guidance. Missed doses may increase the risk of HIV infection. This medicine does not provide protection against other sexually transmitted infections (STIs). Inform your doctor if you have liver problems or liver disease, including hepatitis, kidney problems, or bone problems. This medicine is not suitable for children aged 11 years or younger.
Uses
HIV infection
How it works
Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide analog reverse transcriptase inhibitors, exhibiting their antiviral effect by competing with natural substrates and incorporating them into viral DNA, resulting in the termination of the DNA chain.
How to Use
It is an orally available prescription drug. Your doctor will decide the dose and duration of Taficita tablet based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water. If you have difficulty in swallowing the tablet whole, you can split it in half after consulting with your doctor.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Hepatitis B reactivation Increased risk of fracture Acute renal failure Common Nausea, vomiting
Expert Tips
Your doctor will tell you how much medicine to use. Do not use more than directed. This medicine is used with other medicines to treat HIV infection. Take all other medicines your doctor has prescribed as part of your combination treatment. Do not stop using this medicine without checking first with your doctor. If you stop the medicine even briefly, the virus may become harder to treat. Take this medicine as prescribed by your doctor. Take this medicine with food to decrease nausea and vomiting. Do not skip the medicine or change the dose without consulting the doctor. Always practice safe sex, even if your partner also has HIV. Do not share needles or other items that may have blood or body fluids on them.
References
- Descovy 200 mg/25 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. Published April 2022. Accessed May 20, 2023. https://www.medicines.org.uk/emc/product/2108/smpc
- Emtricitabine / Tenofovir Alafenamide - Patient | NIH. clinicalinfo.hiv.gov. Published February 27, 2023. Accessed May 20, 2023. https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-alafenamide/patient#dr1
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
- Gilead Sciences, Inc., US Food & Drug Administration, [Revised on Sep 2017] [Accessed on 14th Aug 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208215s005lbl.pdf
Safety Advice
Pregnancy: Consult your doctor There is limited information on the use of Taficita tablet during pregnancy. Inform your physician if you are pregnant or planning to get pregnant during the treatment.
Lungs: Consult your doctor It is unknown whether Taficita tablet is safe to be administer in patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Taficita tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.